- Home
- JBHT vs GMAB Comparison
JBHT vs GMAB Comparison
Compare JBHT & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBHT
- GMAB
- Stock Information
- Founded
- JBHT 1961
- GMAB 1999
- Country
- JBHT United States
- GMAB Denmark
- Employees
- JBHT N/A
- GMAB N/A
- Industry
- JBHT Trucking Freight/Courier Services
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- JBHT Industrials
- GMAB Health Care
- Exchange
- JBHT Nasdaq
- GMAB Nasdaq
- Market Cap
- JBHT 15.7B
- GMAB 17.4B
- IPO Year
- JBHT N/A
- GMAB N/A
- Fundamental
- Price
- JBHT $169.73
- GMAB $28.70
- Analyst Decision
- JBHT Buy
- GMAB Strong Buy
- Analyst Count
- JBHT 18
- GMAB 7
- Target Price
- JBHT $168.72
- GMAB $41.17
- AVG Volume (30 Days)
- JBHT 1.7M
- GMAB 2.5M
- Earning Date
- JBHT 10-15-2025
- GMAB 11-06-2025
- Dividend Yield
- JBHT 1.04%
- GMAB N/A
- EPS Growth
- JBHT 5.00
- GMAB 77.72
- EPS
- JBHT 5.77
- GMAB 21.62
- Revenue
- JBHT $12,048,818,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- JBHT $1.34
- GMAB $24.25
- Revenue Next Year
- JBHT $3.80
- GMAB $16.29
- P/E Ratio
- JBHT $29.39
- GMAB $1.33
- Revenue Growth
- JBHT N/A
- GMAB 32.97
- 52 Week Low
- JBHT $122.79
- GMAB $17.24
- 52 Week High
- JBHT $200.40
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- JBHT 67.94
- GMAB 39.01
- Support Level
- JBHT $163.71
- GMAB $29.57
- Resistance Level
- JBHT $171.52
- GMAB $29.30
- Average True Range (ATR)
- JBHT 4.75
- GMAB 0.65
- MACD
- JBHT 0.53
- GMAB -0.50
- Stochastic Oscillator
- JBHT 92.00
- GMAB 7.04
About JBHT J.B. Hunt Transport Services Inc.
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (48% of sales), dedicated trucking services that provide customer-specific fleet needs (27%), for-hire truckload (6%), heavy goods final-mile delivery (7%), and asset-light truck brokerage (12%).
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.